Looks like you clickedhttps://www.urotoday.com/conference-highlights/asco-gu-2023/asco-gu-2023-prostate-cancer/142454-asco-gu-2023-talapro-2-phase-3-study-of-talazoparib-tala-enzalutamide-enza-versus-placebo-pbo-enza-as-first-line-1l-treatment-in-patients-pts-with-metastatic-castration-resistant-prostate-cancer-mcrpc.html
If you do not want to visit that page, you can close this browser tab.
